Biologics
A Focus on Biologic Medicines
BioFutureRx is focused on biologic medicines — spanning biosimilars, novel and first-in-class antibodies, companion diagnostics, and drug-delivery platforms — across oncology, immunology, and other areas of high unmet need.
Our Focus
Biologic medicine across the value chain
Biologics are among the most important and fastest-growing classes of medicine. BioFutureRx concentrates on the areas where differentiated science and development expertise can widen access and address unmet need.
Biosimilars
Widening access to established biologic therapies across oncology, immunology, and other high-need areas.
First-in-Class & Novel Antibodies
Novel-target discovery and antibody engineering aimed at areas of significant unmet medical need.
Companion Diagnostics
Diagnostic and biomarker approaches that pair with therapeutics to enable earlier, more precise treatment.
Delivery Platforms
Drug-delivery innovation — including subcutaneous and ocular routes — that extends how biologics reach patients.
Lead Asset
Our proprietary peptide, BFRx3711
Alongside our focus on biologics, BioFutureRx develops its own peptide therapeutics in-house — led by BFRx3711, a novel long-acting GLP-1 analog designed for potential once-monthly dosing.
Explore the peptide programExplore a partnership
We work with biologics companies seeking to reach the U.S. market, and we welcome conversations about how we can help.